ORIC Q3 2022 Earnings — ORIC Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ORICORIC Pharmaceuticals, Inc.

$1B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$25M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$238M

Total Liabilities

$23M

Stockholders' Equity

$215M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$18M	-39.2%
Net Income	-$25M	-$18M	-34.7%